ACETAMINOPHEN TOXICITY DIAGNOSTICS, LLC

ACETAMINOPHEN TOXICITY DIAGNOSTICS, LLC specializes in the development and validation of diagnostic assays for drug-induced hepatotoxicity, with a focus on biomarker discovery, analytical method validation, and clinical laboratory testing for acetaminophen overdose scenarios. Their technical expertise lies in clinical chemistry, toxicokinetic modeling, and regulatory-compliant assay development under CLIA and CAP frameworks, enabling rapid, accurate quantification of serum biomarkers such as N-acetyl-p-benzoquinone imine adducts and microRNA signatures. The firm’s differentiation stems from its proprietary algorithmic platforms for early toxicity prediction and its integration of in vitro toxicology data with clinical decision support systems, enhancing point-of-care triage in emergency settings. No award history is available to infer specific agency relationships or contracting patterns. Consequently, there is no verifiable data on engagement with federal departments or the nature of work performed for any government entity. The contractor’s primary NAICS code, 541714, corresponds to “Medical and Diagnostic Laboratory,” indicating a focus on clinical testing services, laboratory automation, and diagnostic innovation within the biomedical research and public health sectors. Their market positioning centers on translational toxicology, bridging laboratory research with emergency medicine applications. The entity is structured as a small business (2L) and is headquartered in Little Rock, Arkansas. No government certifications, such as 8(a), HUBZone, or WOSB, are currently listed. The company operates as a specialized diagnostics provider with no public indication of multi-state or federal facility presence beyond its primary location.